FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4315706058> ?p ?o ?g. }

• W4315706058 endingPage "365" @default.
• W4315706058 startingPage "365" @default.
• W4315706058 abstract "Importance Magnetic resonance imaging (MRI) guidance offers multiple theoretical advantages in the context of stereotactic body radiotherapy (SBRT) for prostate cancer. However, to our knowledge, these advantages have yet to be demonstrated in a randomized clinical trial. Objective To determine whether aggressive margin reduction with MRI guidance significantly reduces acute grade 2 or greater genitourinary (GU) toxic effects after prostate SBRT compared with computed tomography (CT) guidance. Design, Setting, and Participants This phase 3 randomized clinical trial (MRI-Guided Stereotactic Body Radiotherapy for Prostate Cancer [MIRAGE]) enrolled men aged 18 years or older who were receiving SBRT for clinically localized prostate adenocarcinoma at a single center between May 5, 2020, and October 1, 2021. Data were analyzed from January 15, 2021, through May 15, 2022. All patients had 3 months or more of follow-up. Interventions Patients were randomized 1:1 to SBRT with CT guidance (control arm) or MRI guidance. Planning margins of 4 mm (CT arm) and 2 mm (MRI arm) were used to deliver 40 Gy in 5 fractions. Main Outcomes and Measures The primary end point was the incidence of acute (≤90 days after SBRT) grade 2 or greater GU toxic effects (using Common Terminology Criteria for Adverse Events, version 4.03 [CTCAE v4.03]). Secondary outcomes included CTCAE v4.03–based gastrointestinal toxic effects and International Prostate Symptom Score (IPSS)–based and Expanded Prostate Cancer Index Composite-26 (EPIC-26)–based outcomes. Results Between May 2020 and October 2021, 156 patients were randomized: 77 to CT (median age, 71 years [IQR, 67-77 years]) and 79 to MRI (median age, 71 years [IQR, 68-75 years]). A prespecified interim futility analysis conducted after 100 patients reached 90 or more days after SBRT was performed October 1, 2021, with the sample size reestimated to 154 patients. Thus, the trial was closed to accrual early. The incidence of acute grade 2 or greater GU toxic effects was significantly lower with MRI vs CT guidance (24.4% [95% CI, 15.4%-35.4%] vs 43.4% [95% CI, 32.1%-55.3%]; P = .01), as was the incidence of acute grade 2 or greater gastrointestinal toxic effects (0.0% [95% CI, 0.0%-4.6%] vs 10.5% [95% CI, 4.7%-19.7%]; P = .003). Magnetic resonance imaging guidance was associated with a significantly smaller percentage of patients with a 15-point or greater increase in IPSS at 1 month (6.8% [5 of 72] vs 19.4% [14 of 74]; P = .01) and a significantly reduced percentage of patients with a clinically significant (≥12-point) decrease in EPIC-26 bowel scores (25.0% [17 of 68] vs 50.0% [34 of 68]; P = .001) at 1 month. Conclusions and Relevance In this randomized clinical trial, compared with CT-guidance, MRI-guided SBRT significantly reduced both moderate acute physician-scored toxic effects and decrements in patient-reported quality of life. Longer-term follow-up will confirm whether these notable benefits persist. Trial Registration ClinicalTrials.gov Identifier: NCT04384770" @default.
• W4315706058 created "2023-01-12" @default.
• W4315706058 creator A5006750331 @default.
• W4315706058 creator A5008476295 @default.
• W4315706058 creator A5013163413 @default.
• W4315706058 creator A5015173784 @default.
• W4315706058 creator A5019566854 @default.
• W4315706058 creator A5021259662 @default.
• W4315706058 creator A5041615709 @default.
• W4315706058 creator A5042160031 @default.
• W4315706058 creator A5044798896 @default.
• W4315706058 creator A5051523579 @default.
• W4315706058 creator A5056932023 @default.
• W4315706058 creator A5060371062 @default.
• W4315706058 creator A5075740763 @default.
• W4315706058 creator A5082455802 @default.
• W4315706058 creator A5089610573 @default.
• W4315706058 creator A5091674984 @default.
• W4315706058 date "2023-03-01" @default.
• W4315706058 modified "2023-10-09" @default.
• W4315706058 title "Magnetic Resonance Imaging–Guided vs Computed Tomography–Guided Stereotactic Body Radiotherapy for Prostate Cancer" @default.
• W4315706058 cites W2004965124 @default.
• W4315706058 cites W2017622807 @default.
• W4315706058 cites W2035429331 @default.
• W4315706058 cites W2103351853 @default.
• W4315706058 cites W2108183929 @default.
• W4315706058 cites W2460652653 @default.
• W4315706058 cites W2519027667 @default.
• W4315706058 cites W2569728867 @default.
• W4315706058 cites W2590373595 @default.
• W4315706058 cites W2767171201 @default.
• W4315706058 cites W2791655860 @default.
• W4315706058 cites W2805351090 @default.
• W4315706058 cites W2887088149 @default.
• W4315706058 cites W2907271500 @default.
• W4315706058 cites W2912734771 @default.
• W4315706058 cites W2913870183 @default.
• W4315706058 cites W2914880936 @default.
• W4315706058 cites W2937088162 @default.
• W4315706058 cites W2952903287 @default.
• W4315706058 cites W2969176485 @default.
• W4315706058 cites W2973514824 @default.
• W4315706058 cites W2993539218 @default.
• W4315706058 cites W2994123442 @default.
• W4315706058 cites W2999081098 @default.
• W4315706058 cites W3017381459 @default.
• W4315706058 cites W3091776643 @default.
• W4315706058 cites W3111425381 @default.
• W4315706058 cites W3122772564 @default.
• W4315706058 cites W3127066344 @default.
• W4315706058 cites W3160719062 @default.
• W4315706058 cites W3185082607 @default.
• W4315706058 cites W3194601649 @default.
• W4315706058 cites W3205015076 @default.
• W4315706058 cites W3212595588 @default.
• W4315706058 cites W4224284961 @default.
• W4315706058 cites W4225013389 @default.
• W4315706058 cites W4226237761 @default.
• W4315706058 cites W4241296147 @default.
• W4315706058 cites W4242608705 @default.
• W4315706058 cites W4247813733 @default.
• W4315706058 doi "https://doi.org/10.1001/jamaoncol.2022.6558" @default.
• W4315706058 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36633877" @default.
• W4315706058 hasPublicationYear "2023" @default.
• W4315706058 type Work @default.
• W4315706058 citedByCount "35" @default.
• W4315706058 countsByYear W43157060582023 @default.
• W4315706058 crossrefType "journal-article" @default.
• W4315706058 hasAuthorship W4315706058A5006750331 @default.
• W4315706058 hasAuthorship W4315706058A5008476295 @default.
• W4315706058 hasAuthorship W4315706058A5013163413 @default.
• W4315706058 hasAuthorship W4315706058A5015173784 @default.
• W4315706058 hasAuthorship W4315706058A5019566854 @default.
• W4315706058 hasAuthorship W4315706058A5021259662 @default.
• W4315706058 hasAuthorship W4315706058A5041615709 @default.
• W4315706058 hasAuthorship W4315706058A5042160031 @default.
• W4315706058 hasAuthorship W4315706058A5044798896 @default.
• W4315706058 hasAuthorship W4315706058A5051523579 @default.
• W4315706058 hasAuthorship W4315706058A5056932023 @default.
• W4315706058 hasAuthorship W4315706058A5060371062 @default.
• W4315706058 hasAuthorship W4315706058A5075740763 @default.
• W4315706058 hasAuthorship W4315706058A5082455802 @default.
• W4315706058 hasAuthorship W4315706058A5089610573 @default.
• W4315706058 hasAuthorship W4315706058A5091674984 @default.
• W4315706058 hasBestOaLocation W43157060581 @default.
• W4315706058 hasConcept C121608353 @default.
• W4315706058 hasConcept C126322002 @default.
• W4315706058 hasConcept C126838900 @default.
• W4315706058 hasConcept C141071460 @default.
• W4315706058 hasConcept C143409427 @default.
• W4315706058 hasConcept C151730666 @default.
• W4315706058 hasConcept C168563851 @default.
• W4315706058 hasConcept C203092338 @default.
• W4315706058 hasConcept C2776235491 @default.
• W4315706058 hasConcept C2777793932 @default.
• W4315706058 hasConcept C2779343474 @default.
• W4315706058 hasConcept C2780192828 @default.
• W4315706058 hasConcept C2780387249 @default.

• next